acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane

C158H190B3Br5IN15O27 — CID 160502551

About acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane

acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (PubChem CID 160502551) has the molecular formula C158H190B3Br5IN15O27 and a molecular weight of 3290.20 g/mol. Its IUPAC name is acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane.

Molecular Properties

• Compound Name: acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane
• PubChem CID: 160502551
• Molecular Formula: C158H190B3Br5IN15O27
• Molecular Weight: 3290.20 g/mol
• Exact Mass: 3283.92
• IUPAC Name: acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane
• SMILES: C=CC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(Br)cc2)C(=O)O1.CC(=O)NN.CC(=O)NNC(=O)CC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(Br)cc2)C(=O)O1.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCC(=O)O)(c2ccccc2)OC1=O.C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O.Cc1nnc(CC[C@]2(c3ccccc3)CCN([C@@H](C)c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)C(=O)O2)o1.Cc1nnc(CC[C@]2(c3ccccc3)CCN([C@@H](C)c3ccc(Br)cc3)C(=O)O2)o1.Cn1ccc(I)cc1=O
• InChI: InChI=1S/C29H36BN3O5.C23H26BrN3O4.C23H24BrN3O3.C21H22BrNO4.C21H24BrNO3.C21H22BrNO2.C12H24B2O4.C6H6INO.C2H6N2O/c1-20(22-12-14-24(15-13-22)30-37-27(3,4)28(5,6)38-30)33-19-18-29(36-26(33)34,23-10-8-7-9-11-23)17-16-25-32-31-21(2)35-25;1-16(18-8-10-20(24)11-9-18)27-15-14-23(31-22(27)30,19-6-4-3-5-7-19)13-12-21(29)26-25-17(2)28;1-16(18-8-10-20(24)11-9-18)27-15-14-23(30-22(27)28,19-6-4-3-5-7-19)13-12-21-26-25-17(2)29-21;1-15(16-7-9-18(22)10-8-16)23-14-13-21(27-20(23)26,12-11-19(24)25)17-5-3-2-4-6-17;1-16(17-8-10-19(22)11-9-17)23-14-13-21(12-5-15-24,26-20(23)25)18-6-3-2-4-7-18;1-3-13-21(18-7-5-4-6-8-18)14-15-23(20(24)25-21)16(2)17-9-11-19(22)12-10-17;1-9(2)10(3,4)16-13(15-9)14-17-11(5,6)12(7,8)18-14;1-8-3-2-5(7)4-6(8)9;1-2(5)4-3/h7-15,20H,16-19H2,1-6H3;3-11,16H,12-15H2,1-2H3,(H,25,28)(H,26,29);3-11,16H,12-15H2,1-2H3;2-10,15H,11-14H2,1H3,(H,24,25);2-4,6-11,16,24H,5,12-15H2,1H3;3-12,16H,1,13-15H2,2H3;1-8H3;2-4H,1H3;3H2,1H3,(H,4,5)/t20-,29+;2*16-,23+;15-,21+;2*16-,21+;;;/m000000.../s1
• InChIKey: QRYYNCIJODPRNT-IIYJXCDOSA-N
• XLogP: 33.07
• TPSA: 503.31 Ų
• H-Bond Donors: 6
• H-Bond Acceptors: 32
• Rotatable Bonds: 37
• Heavy Atoms: 209
• Complexity: —

Lipinski Rule of Five

4 violations

Rule	Value
MW ≤ 500	3290.20
LogP ≤ 5	33.07
H-Bond Donors ≤ 5	6
H-Bond Acceptors ≤ 10	32

Computed Properties (RDKit)

• Structural Alerts: {'alert_name': '>_2_ester_groups', 'substructure': 'N/A'}, {'alert_name': 'acyl_hydrazine', 'substructure': 'N/A'}, {'alert_name': 'heavy_metal', 'substructure': 'N/A'}, {'alert_name': 'hydrazine', 'substructure': 'N/A'}, {'alert_name': 'iodine', 'substructure': 'N/A'}

Frequently Asked Questions

What is the IUPAC name of acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane?

The IUPAC name of acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (CID 160502551) is acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane.

What is the SMILES notation for acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane?

The canonical SMILES for acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane is C=CC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(Br)cc2)C(=O)O1.CC(=O)NN.CC(=O)NNC(=O)CC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(Br)cc2)C(=O)O1.CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C.C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCC(=O)O)(c2ccccc2)OC1=O.C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O.Cc1nnc(CC[C@]2(c3ccccc3)CCN([C@@H](C)c3ccc(B4OC(C)(C)C(C)(C)O4)cc3)C(=O)O2)o1.Cc1nnc(CC[C@]2(c3ccccc3)CCN([C@@H](C)c3ccc(Br)cc3)C(=O)O2)o1.Cn1ccc(I)cc1=O.

What is the InChIKey of acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane?

The InChIKey is QRYYNCIJODPRNT-IIYJXCDOSA-N. The full InChI is InChI=1S/C29H36BN3O5.C23H26BrN3O4.C23H24BrN3O3.C21H22BrNO4.C21H24BrNO3.C21H22BrNO2.C12H24B2O4.C6H6INO.C2H6N2O/c1-20(22-12-14-24(15-13-22)30-37-27(3,4)28(5,6)38-30)33-19-18-29(36-26(33)34,23-10-8-7-9-11-23)17-16-25-32-31-21(2)35-25;1-16(18-8-10-20(24)11-9-18)27-15-14-23(31-22(27)30,19-6-4-3-5-7-19)13-12-21(29)26-25-17(2)28;1-16(18-8-10-20(24)11-9-18)27-15-14-23(30-22(27)28,19-6-4-3-5-7-19)13-12-21-26-25-17(2)29-21;1-15(16-7-9-18(22)10-8-16)23-14-13-21(27-20(23)26,12-11-19(24)25)17-5-3-2-4-6-17;1-16(17-8-10-19(22)11-9-17)23-14-13-21(12-5-15-24,26-20(23)25)18-6-3-2-4-7-18;1-3-13-21(18-7-5-4-6-8-18)14-15-23(20(24)25-21)16(2)17-9-11-19(22)12-10-17;1-9(2)10(3,4)16-13(15-9)14-17-11(5,6)12(7,8)18-14;1-8-3-2-5(7)4-6(8)9;1-2(5)4-3/h7-15,20H,16-19H2,1-6H3;3-11,16H,12-15H2,1-2H3,(H,25,28)(H,26,29);3-11,16H,12-15H2,1-2H3;2-10,15H,11-14H2,1H3,(H,24,25);2-4,6-11,16,24H,5,12-15H2,1H3;3-12,16H,1,13-15H2,2H3;1-8H3;2-4H,1H3;3H2,1H3,(H,4,5)/t20-,29+;2*16-,23+;15-,21+;2*16-,21+;;;/m000000.../s1.

What are the key properties of acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane?

acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane has a molecular weight of 3290.20 g/mol, XLogP of 33.07, 37 rotatable bonds, 6 hydrogen bond donors, and 32 hydrogen bond acceptors.

Where does this data come from?

All data for acetohydrazide;N'-acetyl-3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanehydrazide;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-1,3-oxazinan-2-one;3-[(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-2-oxo-6-phenyl-1,3-oxazinan-6-yl]propanoic acid;(6R)-3-[(1S)-1-(4-bromophenyl)ethyl]-6-phenyl-6-prop-2-enyl-1,3-oxazinan-2-one;4-iodo-1-methylpyridin-2-one;(6R)-6-[2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-6-phenyl-3-[(1S)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]-1,3-oxazinan-2-one;4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane is sourced from PubChem (CID 160502551), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).